Case Studies
Expanding an Oncology Product's Market Share
Opportunity
-
A publicly traded American pharmaceutical company received FDA approval for a small molecule inhibitor for the treatment of a hematologic malignancy after treatment with other similar inhibitors
-
At a recent scientific conference, updated study data was presented showing significant response rates and overall survival with the agent as frontline therapy
Strategy
-
McGA identified the potential opportunity for the company to significantly expand market access beyond the FDA indication to frontline therapy
-
The McGA team conducted an in-depth analysis on the relevant NCCN Guideline and clinical data to develop an NCCN positioning strategy
-
McGA drafted an evidence-based request for NCCN submission before the annual NCCN Panel meeting
Consulting Results
-
The request was submitted to NCCN in time for Panel consideration at the annual Panel meeting
-
As suggested in the request, the NCCN Panel recommended the therapy as frontline in the NCCN Guideline and NCCN Compendium, listed as the first option in front of other agents
-
Outcome propels the therapy into the frontline setting, greatly expanding its potential revenue
Client Impact

Detailed State-level Analysis of High-Impact Legislation for BioPharma
Opportunity
-
Existing laws and pending legislation can be ranked by comparison to model legislation or other metrics developed collaboratively. This detailed analysis can inform strategic stakeholder education and engagement and can be augmented by white paper development and training support.
Strategy
-
McGA conducted a legislative landscape review focusing on how states are regulating a specific issue
(e.g., step therapy) -
The McGA team addressed the following relevant factors
-
What is the scope of the law (eg, what insurance types does it apply to)?
-
Does the law clearly state definitions, purpose, and limitations?
-
What does the law specifically mandate?
-
Consulting Results
-
A detailed report of the results of the legislative landscape was presented to the client
-
Existing laws and/or pending legislation were coded and cataloged, so the client had a clear picture of the issues involved
-
McGA evaluated the strength of the law and developed a better understanding to inform strategic stakeholder education and engagement
Client Impact

-
Strategic advocacy insights related to specific client products were provided to the client
-
Issues potentially limiting product utilization and prescribing by clinicians were identified, giving the client the opportunity to prospectively manage and apply mitigation strategies for shift in utilization